Use of tofacitinib in baricitinib‐refractory atopic dermatitis: An example of JAK inhibitor switching
Pediatric Dermatology · 2024
DOI: 10.1111/pde.15386 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Dermatology, 2024. Verfasst von Bhawuk Dhir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohi…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Dermatitis, Atopic, Purines, Pyrazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Atopic dermatitis (AD) is predominantly mediated by a T‐helper 2 immune system response. While JAK inhibitors have gained treatment approval for AD, data regarding interclass efficacy and therapeutic rationale is lacking. We report a patient with recalcitrant AD who failed baricitinib but demonstrated an excellent response to the pan‐JAK inhibitor tofacitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital, New Delhi, India.
ORCID-Profile: Kabir Sardana
Zitieren
APA
Dhir, B., Meena, S. K., Sardana, K., & Sharath, S. (2024). Use of tofacitinib in baricitinib‐refractory atopic dermatitis: An example of JAK inhibitor switching. Pediatric Dermatology. https://doi.org/10.1111/pde.15386
Vancouver
Dhir B, Meena SK, Sardana K, Sharath S. Use of tofacitinib in baricitinib‐refractory atopic dermatitis: An example of JAK inhibitor switching. Pediatric Dermatology. 2024. doi:10.1111/pde.15386
BibTeX
@article{Dhir2024,
author = {Dhir, Bhawuk and Meena, Sumitra Kumari and Sardana, Kabir and Sharath, Savitha},
title = {Use of tofacitinib in baricitinib‐refractory atopic dermatitis: An example of JAK inhibitor switching},
journal = {Pediatric Dermatology},
year = {2024},
doi = {10.1111/pde.15386}
}
EUVIMED